ID: MRFR/LS/5252-HCR | February 2021 | Region: Global | 85 pages
Autoimmune Disease Diagnostics Market Scenario
Global Autoimmune Disease Diagnostics Market accounted for USD 3300 million and expected to register 7.6% CAGR during the forecast period (2018–2023)
Immune system provides protection to human body by reacting to foreign particles and germs like bacteria and viruses. Sometimes human immune system fails to differentiate between own cells and foreign objects and starts attacking own cells, this medical condition is called autoimmune diseases. The increasing prevalence of autoimmune diseases, increasing healthcare expenditure, and growing awareness autoimmune diseases are expected to drive the growth of the market. Moreover, rising R&D spending and aggressive strategies adopted by the top players such as mergers and acquisitions and new product launches are contributing to the growth of the market. For instance, in October 2017, Abbott acquired Alere Inc. for USD 5300 million, with this deal Abbott will gain control over USD 7000 million diagnostics sales of Alere Inc. and strengthen its position in global autoimmune disease diagnostics market.
The increasing false positive results, and price war between companies may hamper the growth of the market during the assessment period.
Some of the key players in the global autoimmune disease diagnostics market are Siemens Healthcare Private Limited, bioMérieux SA, Bio-rad Laboratories, Beckman Coulter, Inc., AstraZeneca, EUROIMMUN AG, F. Hoffmann-la Roche, Inova Diagnostics, Inc.,Myriad Genetics, Inc., Thermo Fisher Scientific, Trinity Biotech Plc., and Hemagen Diagnostics, Inc.
The global autoimmune disease diagnostics market has been segmented on the basis of disease type, test type, and end-user.
On the basis of disease type, the market has been classified as systemic autoimmune disease, and localized autoimmune disease. The systemic autoimmune disease segment has been further divided into psoriasis, multiple sclerosis, rheumatoid arthritis, systemic lupus erythematosus (SLE), and others. Localized autoimmune disease segment has been classified into inflammatory bowel disease, thyroid, type 1 diabetes, and others.
The test type segment has been divided into western blotting, enzyme-linked immunosorbent assay (ELISA), double immune diffusion, dot blot, counter immune-electrophoresis, line blot, immunofluorescence assays (IFA), multiplex immunoassay, agglutination, and others.
The market, by end-user, has been segmented into hospitals, diagnostics centers, research laboratories, and others.
The market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The autoimmune disease diagnostics market in the Americas has further been segmented into North America and South America, with the North American market divided into the US and Canada.
The European autoimmune disease diagnostics market has been segmented into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The autoimmune disease diagnostics market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The Autoimmune Disease Diagnostics market in the Middle East & Africa has been segmented into the Middle East and Africa.
Regional Market Summary: The Americas are expected to hold the maximum share of global autoimmune disease diagnostics market owing to the increasing prevalence of autoimmune diseases such as rheumatoid arthritis, increasing financial support by government and private organizations, and adoption of highly advanced technology. According to the report published by Arthritis Foundation in 2017, arthritis is serious problem in United states, approximately 91 million Americans were suffering from arthritis, out of which 300000 were children.
Global Autoimmune Disease Diagnostics Market Share, by Region , 2017 (%)
Source: MRFR Analysis
The European market is likely to be the second-largest autoimmune disease diagnostics market. The market growth in this region can be attributed to the increasing automation in laboratories, growing healthcare industry, and aggressive strategies implemented by major players in the region. For instance, in November 2018, bioMérieux SA bought majority shares in Suzhou Hybiome Biomedical Engineering Co. Ltd, with this deal the company will strengthen its position in immunoassay market and also help the help to enter into the Chinese market.
Asia-Pacific is expected to be the fastest-growing autoimmune disease diagnostics market during the forecast period owing to the rising population, increasing prevalence of autoimmune disorders, and increasing private-public partnerships for improvement of healthcare sector. According to the Arthritis Foundation of Asia, 47 percent of adults with diabetes and 49 percent heart patients are suffering from arthritis, this percentage in likely to increase in the future and burden of autoimmune diseases will cost a fortune to the healthcare sector.
The market in the Middle East & Africa is expected to hold the smallest share of the global autoimmune disease diagnostics market due to an underdeveloped healthcare sector, lack of technical knowledge, and poor medical facilities.
Global Autoimmune Disease Diagnostics Market, by Disease Type
Global Autoimmune Disease Diagnostics Market, by Test Type
Global Autoimmune Disease Diagnostics Market, by End-User
Global Autoimmune Disease Diagnostics Market, by Region
Frequently Asked Questions (FAQ) :
The autoimmune disease diagnostics market is projected to grow at a 7.6% CAGR between 2018-2023.
The autoimmune disease diagnostics market is predicted to touch USD 3300 million by 2023.
The Americas is projected to command the largest share in the autoimmune disease diagnostics market.
Increasing healthcare expenditure and rising prevalence of autoimmune diseases are boosting market growth.
Price war may limit market growth.